ABSK211 in people with KRAS-altered advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open-label Phase 1 trial starting with dose escalation of an oral ABSK211 to determine safety, tolerability, and pharmacokinetics in participants with KRAS-altered advanced solid tumors. After identifying recommended doses, the study expands to evaluate safety and preliminary efficacy in selected tumor types harboring KRAS alterations. The trial will monitor adverse events, drug exposure, and dosing to optimize the regimen. Enrollment is limited to adults with adequate organ function and a performance status of 0 or 1. Exclusions include allergy to the drug, prior KRAS-targeted inhibitors, and other active malignancies requiring treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants should understand, sign, and date the written informed consent form prior to screening.
2. Male or female age 18 years or older
3. Participants with histologically confirmed locally-advanced or metastatic solid tumors harboring KRAS alteration
4. ECOG performance status 0 or 1
5. Life expectancy ≥ 3 months
6. Adequate organ function and bone marrow function
7. For participants participating exploration of food effect:

1)be able to eat a standardized high-fat, high caloric meal within 30 minutes. 2) be able to fast for 10 hours.

Exclusion Criteria:

1. Known allergy or hypersensitivity to any component of the investigational product
2. Participants who were previously treated with any inhibitors targeting specific KRAS alleles, pan-KRAS inhibitors, pan- or multi-RAS inhibitors, or any other treatments directly targeting RAS.
3. Has a known additional malignancy that is progressing or has required active treatment
4. Has swallowing dysfunction or malabsorption syndrome
5. Previous anti-tumor therapy, including chemotherapy ,endocrine therapy, molecular targeted therapy or other investigational drugs received ≤2 weeks or ≤5-half life ,radiotherapy and antibody therapy received ≤4 weeks prior to initiation of study treatment.
6. Major surgery within 4 weeks of the first dose of investigational product or with any unhealed surgical wounds, infection or dehiscence.
7. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy, that have not regressed to Grade ≤1 severity;
8. Participants use proton pump inhibitors for at least 7 days prior to the first dose of ABSK211 and during treatment with ABSK211.
9. P-gp inhibitor, moderate and strong CYP3A inhibitors to 7 days or 5 half-lives and for strong CYP3A inducers to 2 weeks or 5 half-lives ;
10. Active central nervous system (CNS) metastases;
11. History of interstitial lung disease (ILD) requiring systemic steroid treatment;
12. Heart disease or medical history ;
13. NSCLC cohorts: Participant previously identified as having a driver mutation and have not received any targeted therapy;
14. Known acquired immunodeficiency syndrome (AIDS)-related illness, or positive test for HIV 1/2 antibody;
15. Exclusion of hepatitis infection;
16. Participants with refractory/uncontrolled ascites or pleural effusion;
17. Pregnant or nursing (lactating) women;
18. Partners of non-surgically sterilized male participants or female participants of childbearing potential who refuse to use effective methods of birth control during the study and for up to 6 months after the last dose of investigational product;
19. Sexually active males who refuse to use a condom during medication period and until 3 months after stopping investigational product;
20. Vaccination with a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment except for administration of inactivate vaccines ;
21. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition;

    \-

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Xianjun Yu, Doctor — Fudan University
• Study coordinator: Lijun Zheng, Master
• Email: lijun.zheng@abbisko.com
• Phone: +86-021-68912098

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

• AN4035 in advanced cancers with RAS mutations and high CEACAM5 expression

  This first-in-human trial tests AN4035 to see if it is safe, tolerable, and possibly active in people with RAS-mutated, CEACAM5-positive advanced solid tumors, including when given with cetuximab.

  Recruiting at 2 sites Phase 1 Adlai Nortye Biopharma Co., Ltd. · Perth and 1 other locations · NCT07686445

• How ABSK-011 behaves in the body with different meals and with an acid reducer in healthy people

  This study tests how meal fat content and omeprazole affect how ABSK-011 capsules move through the body in healthy adults.

  Recruiting Phase 1 Abbisko Therapeutics Co, Ltd · Wuxi · NCT07700953

• ABSK141 for advanced solid tumors with KRAS G12D mutation

  This trial tests an oral drug called ABSK141 to see if it is safe and helps adults with advanced solid tumors that have a KRAS G12D mutation.

  Recruiting Phase 1/2 Abbisko Therapeutics Co, Ltd · Shanghai · NCT07417189

• ABSK-011 plus supportive care versus placebo for previously treated advanced liver cancer with FGF19 overexpression

  This trial tests whether adding ABSK-011 to best supportive care helps people with advanced hepatocellular carcinoma (HCC) whose tumors overexpress FGF19 after prior systemic therapy.

  Recruiting at 49 sites Phase 2 Abbisko Therapeutics Co, Ltd · Hefei, Anhui and 50 other locations · NCT07327034

• Observing children with achondroplasia over time

  Collecting growth, clinical, and quality-of-life information from children with achondroplasia aged 2.5 to under 11 to see how the condition and treatments affect them over 6 months to 2 years.

  Recruiting at 3 sites Abbisko Therapeutics Co, Ltd · Beijing, Beijing Municipality and 7 other locations · NCT07301463

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.